A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
== External links == "Oliceridine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on January 23, 2022. Clinical trial number NCT02815709 for "Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy (APOLLO-1)" at ClinicalTrials.gov Clinical trial number NCT02820324 for "Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty" at ClinicalTrials.gov
== Philanthropy == McGregor is involved in charity work, including UNICEF UK since 2004 and GO Campaign. During the Long Way Round journey in 2004, McGregor and his travelling companions saw some of UNICEF's work in Ukraine, Kazakhstan, and Mongolia, and during the Long Way Down trip in 2007, he and Charley Boorman did some work for UNICEF in Africa. McGregor hosted the annual Hollywood gala for the GO Campaign in 2009 and 2010. He has worked with the Children's Hospice Association Scotland, as featured in Long Way Down. In 2012, he travelled with UNICEF immunisation workers to remote parts of India, Nepal and the Republic of Congo for a BBC2 documentary entitled Ewan McGregor: Cold Chain Mission. In June 2015, McGregor read Hans Christian Andersen's "The Little Match Girl" for the children's fairy tales app GivingTales in aid of UNICEF, together with other prominent figures such as Sir Roger Moore, Stephen Fry, Dame Joan Collins, Joanna Lumley, and Sir Michael Caine.
=== Cultivation theory === George Gerbner's cultivation theory suggests heavy media exposure leads to a distorted view of reality. First-order cultivation leads viewers to believe that the social environment present within media reflects the real-world. Second-order cultivation leads to viewers forming attitudes, opinions, and beliefs due to this media exposure. Therefore, when people encounter the same portrayals and patterns of mental illness through the media, they form beliefs that are consistent with those portrayals. As the number of cases of violence perpetrated by mentally ill characters is higher in media than in reality, this misrepresentation can cause heavy media viewers to falsely believe that mentally ill people are more violent than they are in reality.
Sources: en.wikipedia.org
Phosphorylation of the anionic site by cholinesterase inhibitors prevents the binding of acetylcholine on acetylcholinesterase and butyrylcholine on butyrylcholinesterase respectively. As a result, acetylcholine and butyrylcholine will accumulate in the neuromuscular junction.
A sixth position can reversibly bind oxygen by a coordinate covalent bond, completing the octahedral group of six ligands. This reversible bonding with oxygen is why hemoglobin is so useful for transporting oxygen around the body. Oxygen binds in an "end-on bent" geometry where one oxygen atom binds to Fe and the other protrudes at an angle. When oxygen is not bound, a very weakly bonded water molecule fills the site, forming a distorted octahedron. Even though carbon dioxide is carried by hemoglobin, it does not compete with oxygen for the iron-binding positions but is bound to the amine groups of the protein chains attached to the heme groups. The iron ion may be either in the ferrous Fe2+ or in the ferric Fe3+ state, but ferrihemoglobin (methemoglobin) (Fe3+) cannot bind oxygen. In binding, oxygen temporarily and reversibly oxidizes (Fe2+) to (Fe3+) while oxygen temporarily turns into the superoxide ion, thus iron must exist in the +2 oxidation state to bind oxygen. If superoxide ion associated to Fe3+ is protonated, the hemoglobin iron will remain oxidized and incapable of binding oxygen. In such cases, the enzyme methemoglobin reductase will be able to eventually reactivate methemoglobin by reducing the iron center. In adult humans, the most common hemoglobin type is a tetramer (which contains four subunit proteins) called hemoglobin A, consisting of two α and two β subunits non-covalently bound, each made of 141 and 146 amino acid residues, respectively. This is denoted as α2β2. The subunits are structurally similar and about the same size.
In February 2018, logistics mismanagement by DHL, which had been selected by KFC UK as their new delivery partner, caused a chicken shortage in the United Kingdom – KFC's largest market in Europe – forcing the company to temporarily close hundreds of restaurants around the country. KFC apologized by taking out adverts in British newspapers showing the company's initials rearranged to read "FCK", followed by an apology, which was well received. In November 2021, Finland's first KFC restaurant was opened at the Itis shopping center in Itäkeskus, Helsinki. A few days before the opening day, a tent had appeared in front of the restaurant, where a man who had kept his identity secret for a few days had stayed, and who on the opening day revealed himself to the public as a vegan activist defending animal rights. After trying to give his speech to those present, the security company carried him away. Even before the opening of the restaurant, in October, news of a controversy over the procurement of a broiler for food from Poland; the cause is mainly related to the risk of salmonella in broilers, which is a significant problem in Poland, whereas its prevalence in Finland is low. Following the 2022 Russian invasion of Ukraine, a number of companies have faced growing pressure to halt operations in Russia but have not yet done so. This includes KFC, which has over 1,000 outlets in Russia, more than any other Western fast food chain. However, within a few years, all Russian KFC restaurants were rebranded as "Rostic's".
== Chemistry == Chlorphenamine is an alkylamine and is a part of a series of antihistamines including pheniramine (Naphcon) and its halogenated derivatives including fluorpheniramine, dexchlorphenamine (Polaramine), brompheniramine (Dimetapp), dexbrompheniramine (Drixoral), deschlorpheniramine, and iodopheniramine. The halogenated alkylamine antihistamines all exhibit optical isomerism, and chlorphenamine in the indicated products is racemic chlorphenamine maleate, whereas dexchlorphenamine is the dextrorotary stereoisomer.
Sources: en.wikipedia.org
=== Groupings and organizations === Lucha Libre AAA Worldwide, a Mexican wrestling promotion Asian Athletics Association, the continental athletics authority in Asia Amateur Athletic Association of England, the Athletic Association in England Arkansas Activities Association, for high school sports Montreal AAA, an amateur athletic association Triple-A (baseball), a North American Minor League Baseball classification level Senior ice hockey § Senior AAA hockey leagues
Janusz Boleslaw Pawliszyn (Polish pronunciation: [ˈjanuʂ pavˈliʂɨn]; born May 16, 1954) is a Polish chemist. He is a Canada Research Chair at the University of Waterloo and Natural Sciences and Engineering Research Council of Canada Industrial Research Chair in New Analytical Methods and Technologies.
Early specimens represent birds that were pets or came from menageries. The oldest surviving bird specimens include an African grey parrot once owned by Frances Teresa Stuart (1647–1702) that was buried with its owner in London’s Westminster Abbey. Several mummified ibis and falcons have been recorded from Egyptian tombs dating from 600 to 300 BC. Bird specimens obtained from the 18th century for natural history collections were most often obtained using firearms. Shotguns with "dust" shot were preferred to reduce damage to the specimens. Today, specimens come from a variety of sources. Many (perhaps most) are salvaged from birds killed by window and communications tower strikes, domestic cats, by-catch from fisheries, die-offs from disease, vehicle strikes, and other accidental sources of mortality. However, the world's bird collections have been argued to be inadequate in documenting avian diversity, from taxonomic, geographic, and temporal perspectives, with some parts of tropical regions considered under-represented in particular museums. Underrepresented taxa continue to be actively collected by ornithologists, generally using either firearms or mist-nets. Permitting agencies oversee these activities in most countries.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.